{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:49:49Z","timestamp":1790786989816,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007210","name":"RWTH Aachen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007210","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Orthop Surg Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Osteoporosis affects mostly postmenopausal women, leading to deterioration of the microarchitectural bone structure and low bone mass, with an increased fracture risk with associated disability, morbidity and mortality. This Bayesian network meta-analysis compared the effects of current anti-osteoporosis drugs on bone mineral density.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The present systematic review and network meta-analysis follows the PRISMA extension statement to report systematic reviews incorporating network meta-analyses of health care interventions. The literature search was performed in June 2021. All randomised clinical trials that have investigated the effects of two or more drug treatments on BMD for postmenopausal osteoporosis were accessed. The network comparisons were performed through the STATA Software\/MP routine for Bayesian hierarchical random-effects model analysis. The inverse variance method with standardised mean difference (SMD) was used for analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Data from 64 RCTs involving 82,732 patients were retrieved. The mean follow-up was 29.7 \u00b1 19.6 months. Denosumab resulted in a higher spine BMD (SMD \u22120.220; SE 3.379), followed by pamidronate (SMD \u22125.662; SE 2.635) and zoledronate (SMD \u221210.701; SE 2.871). Denosumab resulted in a higher hip BMD (SMD \u22120.256; SE 3.184), followed by alendronate (SMD \u221217.032; SE 3.191) and ibandronate (SMD \u221217.250; SE 2.264). Denosumab resulted in a higher femur BMD (SMD 0.097; SE 2.091), followed by alendronate (SMD \u221216.030; SE 1.702) and ibandronate (SMD \u221217.000; SE 1.679).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Denosumab results in higher spine BMD in selected women with postmenopausal osteoporosis. Denosumab had the highest influence on hip and femur BMD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Level of evidence<\/jats:title>\n                <jats:p>Level I, Bayesian network meta-analysis of RCTs<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13018-021-02678-x","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T05:02:57Z","timestamp":1630040577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7220-1221","authenticated-orcid":false,"given":"Filippo","family":"Migliorini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maffulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Colarossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Eschweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Tingart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Betsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"2678_CR1","doi-asserted-by":"publisher","first-page":"759","DOI":"10.2147\/IJWH.S53489","volume":"6","author":"A Modi","year":"2014","unstructured":"Modi A, Sajjan S, Gandhi S. Challenges in implementing and maintaining osteoporosis therapy. Int J Women's Health. 2014;6:759\u201369.","journal-title":"Int J Women's Health"},{"issue":"10169","key":"2678_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(18)32112-3.","journal-title":"Lancet"},{"issue":"9","key":"2678_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra067395","volume":"357","author":"E Canalis","year":"2007","unstructured":"Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357(9):905\u201316. https:\/\/doi.org\/10.1056\/NEJMra067395.","journal-title":"N Engl J Med"},{"issue":"1","key":"2678_CR4","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1530\/EJE-18-0056","volume":"179","author":"AD Anastasilakis","year":"2018","unstructured":"Anastasilakis AD, Polyzos SA, Makras P. Therapy of endocrine disease: denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis. Eur J Endocrinol. 2018;179(1):R31\u201345. https:\/\/doi.org\/10.1530\/EJE-18-0056.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2678_CR5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1006\/bbrc.1999.1499","volume":"264","author":"E van Beek","year":"1999","unstructured":"van Beek E, Pieterman E, Cohen L, L\u00f6wik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999;264(1):108\u201311. https:\/\/doi.org\/10.1006\/bbrc.1999.1499.","journal-title":"Biochem Biophys Res Commun"},{"issue":"20","key":"2678_CR6","doi-asserted-by":"publisher","first-page":"7829","DOI":"10.1073\/pnas.0601643103","volume":"103","author":"KL Kavanagh","year":"2006","unstructured":"Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A. 2006;103(20):7829\u201334. https:\/\/doi.org\/10.1073\/pnas.0601643103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2678_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637\u201345. https:\/\/doi.org\/10.1001\/jama.282.7.637.","journal-title":"JAMA"},{"issue":"8","key":"2678_CR8","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1359\/jbmr.070413","volume":"22","author":"P Chen","year":"2007","unstructured":"Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res. 2007;22(8):1173\u201380. https:\/\/doi.org\/10.1359\/jbmr.070413.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2678_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00223-016-0171-1","volume":"99","author":"H Bahar","year":"2016","unstructured":"Bahar H, Gallacher K, Downall J, Nelson CA, Shomali M, Hattersley G. Six weeks of daily abaloparatide treatment increased vertebral and femoral bone mineral density, microarchitecture and strength in ovariectomized osteopenic rats. Calcif Tissue Int. 2016;99(5):489\u201399. https:\/\/doi.org\/10.1007\/s00223-016-0171-1.","journal-title":"Calcif Tissue Int"},{"issue":"16","key":"2678_CR10","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1607948.","journal-title":"N Engl J Med"},{"issue":"15","key":"2678_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1708322.","journal-title":"N Engl J Med"},{"issue":"11","key":"2678_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777\u201384. https:\/\/doi.org\/10.7326\/M14-2385.","journal-title":"Ann Intern Med"},{"key":"2678_CR13","unstructured":"Howick J CI, Glasziou P, Greenhalgh T, Carl Heneghan, Liberati A, Moschetti I, Phillips B, Thornton H, Goddard O, Hodgkinson M. 2011. The 2011 Oxford CEBM levels of evidence. Oxford Centre for Evidence-Based Medicine Available at https:\/\/www.cebmnet\/indexaspx?o=5653."},{"issue":"7","key":"2678_CR14","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J, Bianic F, Campbell R, et al. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465\u201373. https:\/\/doi.org\/10.1007\/s00198-019-04947-2.","journal-title":"Osteoporos Int"},{"issue":"8","key":"2678_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1097\/GME.0000000000001321","volume":"26","author":"X Tan","year":"2019","unstructured":"Tan X, Wen F, Yang W, Xie JY, Ding LL, Mo YX. Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: a network meta-analysis (Chongqing, China). Menopause. 2019;26(8):929\u201339. https:\/\/doi.org\/10.1097\/GME.0000000000001321.","journal-title":"Menopause"},{"issue":"3-4","key":"2678_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1159\/000453138","volume":"40","author":"XC Yang","year":"2016","unstructured":"Yang XC, Deng ZH, Wen T, Luo W, Xiao WF, Zhao RB, et al. Network meta-analysis of pharmacological agents for osteoporosis treatment and fracture prevention. Cell Physiol Biochem. 2016;40(3-4):781\u201395. https:\/\/doi.org\/10.1159\/000453138.","journal-title":"Cell Physiol Biochem"},{"key":"2678_CR17","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P, et al. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone. 2020;130:115081. https:\/\/doi.org\/10.1016\/j.bone.2019.115081.","journal-title":"Bone"},{"issue":"7","key":"2678_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.11622\/smedj.2019028","volume":"60","author":"T Chandran","year":"2019","unstructured":"Chandran T, Venkatachalam I. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review. Singap Med J. 2019;60(7):364\u201378. https:\/\/doi.org\/10.11622\/smedj.2019028.","journal-title":"Singap Med J"},{"issue":"8","key":"2678_CR19","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00198-009-1008-9","volume":"20","author":"E Sornay-Rendu","year":"2009","unstructured":"Sornay-Rendu E, Boutroy S, Munoz F, Bouxsein ML. Cortical and trabecular architecture are altered in postmenopausal women with fractures. Osteoporos Int. 2009;20(8):1291\u20137. https:\/\/doi.org\/10.1007\/s00198-009-1008-9.","journal-title":"Osteoporos Int"},{"issue":"3","key":"2678_CR20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1517\/17425255.2015.1000860","volume":"11","author":"S Zaheer","year":"2015","unstructured":"Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol. 2015;11(3):461\u201370. https:\/\/doi.org\/10.1517\/17425255.2015.1000860.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"2678_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u201323. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2678_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/GME.0b013e31828f5e5d","volume":"21","author":"DL Kendler","year":"2014","unstructured":"Kendler DL, Macarios D, Lillestol MJ, Moffett A, Satram-Hoang S, Huang J, et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause. 2014;21(1):25\u201332. https:\/\/doi.org\/10.1097\/GME.0b013e31828f5e5d.","journal-title":"Menopause"},{"issue":"3","key":"2678_CR23","doi-asserted-by":"publisher","first-page":"E487","DOI":"10.1210\/jc.2014-3594","volume":"100","author":"S Palacios","year":"2015","unstructured":"Palacios S, Agodoa I, Bonnick S, van den Bergh JP, Ferreira I, Ho PR, et al. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate. J Clin Endocrinol Metab. 2015;100(3):E487\u201392. https:\/\/doi.org\/10.1210\/jc.2014-3594.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2678_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153\u201361. https:\/\/doi.org\/10.1359\/jbmr.0809010.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2678_CR25","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72\u201381. https:\/\/doi.org\/10.1359\/jbmr.090716.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2678_CR26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","volume":"121","author":"C Recknor","year":"2013","unstructured":"Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, et al. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013;121(6):1291\u20139. https:\/\/doi.org\/10.1097\/AOG.0b013e318291718c.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"2678_CR27","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, Delmas PD, Hanley DA, Sellmeyer D, Cheung AM, Shane E, et al. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886\u201394. https:\/\/doi.org\/10.1002\/jbmr.81.","journal-title":"J Bone Miner Res"},{"key":"2678_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","volume":"59","author":"RM Zebaze","year":"2014","unstructured":"Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173\u20139. https:\/\/doi.org\/10.1016\/j.bone.2013.11.016.","journal-title":"Bone"},{"issue":"10","key":"2678_CR29","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","volume":"26","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int. 2015;26(10):2521\u20137. https:\/\/doi.org\/10.1007\/s00198-015-3174-2.","journal-title":"Osteoporos Int"},{"issue":"18","key":"2678_CR30","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809\u201322. https:\/\/doi.org\/10.1056\/NEJMoa067312.","journal-title":"N Engl J Med"},{"issue":"10","key":"2678_CR31","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1210\/jc.2002-020334","volume":"87","author":"JJ Body","year":"2002","unstructured":"Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87(10):4528\u201335. https:\/\/doi.org\/10.1210\/jc.2002-020334.","journal-title":"J Clin Endocrinol Metab"},{"key":"2678_CR32","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535\u201341.","journal-title":"Lancet"},{"issue":"24","key":"2678_CR33","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927\u201338. https:\/\/doi.org\/10.1001\/jama.296.24.2927.","journal-title":"JAMA"},{"issue":"2","key":"2678_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243\u201354. https:\/\/doi.org\/10.1002\/jbmr.1494.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2678_CR35","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/jbmr.2442","volume":"30","author":"DM Black","year":"2015","unstructured":"Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934\u201344. https:\/\/doi.org\/10.1002\/jbmr.2442.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2678_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1210\/jcem.82.1.3682","volume":"82","author":"HG Bone","year":"1997","unstructured":"Bone HG, Downs RW Jr, Tucci JR, et al. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. J Clin Endocrinol Metab. 1997;82(1):265\u201374. https:\/\/doi.org\/10.1210\/jcem.82.1.3682.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2678_CR37","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1007\/s00198-014-2692-7","volume":"25","author":"JP Brown","year":"2014","unstructured":"Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int. 2014;25(7):1953\u201361. https:\/\/doi.org\/10.1007\/s00198-014-2692-7.","journal-title":"Osteoporos Int"},{"issue":"6","key":"2678_CR38","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","volume":"17","author":"C Brumsen","year":"2002","unstructured":"Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PHLM, Hamdy NAT, Landman JO, et al. Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res. 2002;17(6):1057\u201364. https:\/\/doi.org\/10.1359\/jbmr.2002.17.6.1057.","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2678_CR39","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"CH Chesnut 3rd","year":"2004","unstructured":"Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241\u20139. https:\/\/doi.org\/10.1359\/JBMR.040325.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2678_CR40","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/PL00004152","volume":"7","author":"B Clemmesen","year":"1997","unstructured":"Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int. 1997;7(5):488\u201395. https:\/\/doi.org\/10.1007\/PL00004152.","journal-title":"Osteoporos Int"},{"issue":"24","key":"2678_CR41","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077\u201382. https:\/\/doi.org\/10.1001\/jama.280.24.2077.","journal-title":"JAMA"},{"issue":"8","key":"2678_CR42","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365. https:\/\/doi.org\/10.1056\/NEJMoa0809493.","journal-title":"N Engl J Med"},{"issue":"8","key":"2678_CR43","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","volume":"87","author":"PD Delmas","year":"2002","unstructured":"Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87(8):3609\u201317. https:\/\/doi.org\/10.1210\/jcem.87.8.8750.","journal-title":"J Clin Endocrinol Metab"},{"key":"2678_CR44","first-page":"1895","volume":"85","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000;85:1895\u2013900.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2678_CR45","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2165\/00044011-199815030-00008","volume":"15","author":"B Frediani","year":"1998","unstructured":"Frediani B, Allegri A, B S, et al. Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis two years of continuous treatment. Clin Drug Investig. 1998;15(3):235\u201344. https:\/\/doi.org\/10.2165\/00044011-199815030-00008.","journal-title":"Clin Drug Investig"},{"key":"2678_CR46","first-page":"6","volume":"3","author":"MAA Jain","year":"2015","unstructured":"Jain MAA, Garg R. A comparative study of use of zoledronic acid and teriparatide in postmenopausal osteoporosis. J South Asian Feder Menopause Soc. 2015;3:6\u20138.","journal-title":"J South Asian Feder Menopause Soc"},{"key":"2678_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bone.2013.12.017","volume":"61","author":"S Gonnelli","year":"2014","unstructured":"Gonnelli S, Caffarelli C, Tanzilli L, Pondrelli C, Lucani B, Franci BM, et al. Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone. 2014;61:27\u201332. https:\/\/doi.org\/10.1016\/j.bone.2013.12.017.","journal-title":"Bone"},{"issue":"6","key":"2678_CR48","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/jamainternmed.2015.0747","volume":"175","author":"SL Greenspan","year":"2015","unstructured":"Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. JAMA Intern Med. 2015;175(6):913\u201321. https:\/\/doi.org\/10.1001\/jamainternmed.2015.0747.","journal-title":"JAMA Intern Med"},{"issue":"2","key":"2678_CR49","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1210\/jc.2008-2241","volume":"94","author":"A Grey","year":"2009","unstructured":"Grey A, Bolland MJ, Wattie D, Horne A, Gamble G, Reid IR. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab. 2009;94(2):538\u201344. https:\/\/doi.org\/10.1210\/jc.2008-2241.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2678_CR50","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1210\/jc.2011-2081","volume":"97","author":"A Grey","year":"2012","unstructured":"Grey A, Bolland M, Wong S, Horne A, Gamble G, Reid IR. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(1):286\u201392. https:\/\/doi.org\/10.1210\/jc.2011-2081.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2678_CR51","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1002\/hep.26466","volume":"58","author":"N Guanabens","year":"2013","unstructured":"Guanabens N, Monegal A, Cerda D, et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology. 2013;58(6):2070\u20138. https:\/\/doi.org\/10.1002\/hep.26466.","journal-title":"Hepatology"},{"issue":"6","key":"2678_CR52","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","volume":"95","author":"ST Harris","year":"1993","unstructured":"Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95(6):557\u201367. https:\/\/doi.org\/10.1016\/0002-9343(93)90350-X.","journal-title":"Am J Med"},{"key":"2678_CR53","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344\u201352.","journal-title":"JAMA"},{"issue":"3","key":"2678_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/13697130500118126","volume":"8","author":"MJ Hooper","year":"2005","unstructured":"Hooper MJ, Ebeling PR, Roberts AP, Graham JJ, Nicholson GC, D'Emden M, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric. 2005;8(3):251\u201362. https:\/\/doi.org\/10.1080\/13697130500118126.","journal-title":"Climacteric"},{"issue":"1","key":"2678_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3349\/ymj.2008.49.1.119","volume":"49","author":"J Iwamoto","year":"2008","unstructured":"Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J. 2008;49(1):119\u201328. https:\/\/doi.org\/10.3349\/ymj.2008.49.1.119.","journal-title":"Yonsei Med J"},{"issue":"12","key":"2678_CR56","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, et al. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019;30(12):2437\u201348. https:\/\/doi.org\/10.1007\/s00198-019-05146-9.","journal-title":"Osteoporos Int"},{"issue":"10102","key":"2678_CR57","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(17)31613-6.","journal-title":"Lancet"},{"issue":"9999","key":"2678_CR58","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5.","journal-title":"Lancet"},{"issue":"5","key":"2678_CR59","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SAM, Zhu Y, Foley K, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99(5):1694\u2013700. https:\/\/doi.org\/10.1210\/jc.2013-4440.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2678_CR60","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/jbmr.3622","volume":"34","author":"EM Lewiecki","year":"2019","unstructured":"Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, Ebeling PR, Adachi JD, Miyauchi A, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 2019;34(3):419\u201328. https:\/\/doi.org\/10.1002\/jbmr.3622.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2678_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/os.12307","volume":"9","author":"BC Liang","year":"2017","unstructured":"Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, et al. Intravenous zoledronic acid 5 mg on bone turnover markers and bone mineral density in East China subjects with newly diagnosed osteoporosis: a 24-month clinical study. Orthop Surg. 2017;9(1):103\u20139. https:\/\/doi.org\/10.1111\/os.12307.","journal-title":"Orthop Surg"},{"issue":"11","key":"2678_CR62","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","volume":"13","author":"EG Lufkin","year":"1998","unstructured":"Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res. 1998;13(11):1747\u201354. https:\/\/doi.org\/10.1359\/jbmr.1998.13.11.1747.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2678_CR63","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF02242451","volume":"16","author":"GP Lyritis","year":"1997","unstructured":"Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clin Rheumatol. 1997;16(4):354\u201360. https:\/\/doi.org\/10.1007\/BF02242451.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2678_CR64","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1305224.","journal-title":"N Engl J Med"},{"issue":"5","key":"2678_CR65","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","volume":"114","author":"M McClung","year":"2009","unstructured":"McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol. 2009;114(5):999\u20131007. https:\/\/doi.org\/10.1097\/AOG.0b013e3181bdce0a.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"2678_CR66","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8):1397\u2013406. https:\/\/doi.org\/10.1002\/jbmr.3452.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2678_CR67","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"PJ Meunier","year":"2004","unstructured":"Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459\u201368. https:\/\/doi.org\/10.1056\/NEJMoa022436.","journal-title":"N Engl J Med"},{"issue":"10","key":"2678_CR68","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s00198-008-0825-6","volume":"20","author":"PJ Meunier","year":"2009","unstructured":"Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. 2009;20(10):1663\u201373. https:\/\/doi.org\/10.1007\/s00198-008-0825-6.","journal-title":"Osteoporos Int"},{"issue":"8","key":"2678_CR69","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016;101(8):3163\u201370. https:\/\/doi.org\/10.1210\/jc.2016-1801.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2678_CR70","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/BF01623461","volume":"7","author":"ML Montessori","year":"1997","unstructured":"Montessori ML, Scheele WH, Netelenbos JC, et al. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporos Int. 1997;7(1):52\u20138. https:\/\/doi.org\/10.1007\/BF01623461.","journal-title":"Osteoporos Int"},{"issue":"10","key":"2678_CR71","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00198-003-1424-1","volume":"14","author":"H Morii","year":"2003","unstructured":"Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int. 2003;14(10):793\u2013800. https:\/\/doi.org\/10.1007\/s00198-003-1424-1.","journal-title":"Osteoporos Int"},{"issue":"2","key":"2678_CR72","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1210\/jcem.83.2.4586","volume":"83","author":"L Mortensen","year":"1998","unstructured":"Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab. 1998;83(2):396\u2013402. https:\/\/doi.org\/10.1210\/jcem.83.2.4586.","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"2678_CR73","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434\u201341. https:\/\/doi.org\/10.1056\/NEJM200105103441904.","journal-title":"N Engl J Med"},{"issue":"12","key":"2678_CR74","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","volume":"25","author":"MA Paggiosi","year":"2014","unstructured":"Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2014;25(12):2729\u201341. https:\/\/doi.org\/10.1007\/s00198-014-2817-z.","journal-title":"Osteoporos Int"},{"issue":"3","key":"2678_CR75","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/jbmr.1479","volume":"27","author":"S Papapoulos","year":"2012","unstructured":"Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwi\u0144ski E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694\u2013701. https:\/\/doi.org\/10.1002\/jbmr.1479.","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2678_CR76","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C, Lin CJF, Kendler DL, Lewiecki EM, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773\u201383. https:\/\/doi.org\/10.1007\/s00198-015-3234-7.","journal-title":"Osteoporos Int"},{"issue":"3","key":"2678_CR77","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.maturitas.2013.12.013","volume":"77","author":"AW Popp","year":"2014","unstructured":"Popp AW, Buffat H, Cavelti A, Windolf M, Perrelet R, Senn C, et al. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON. Maturitas. 2014;77(3):287\u201393. https:\/\/doi.org\/10.1016\/j.maturitas.2013.12.013.","journal-title":"Maturitas"},{"issue":"6","key":"2678_CR78","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bone.2009.08.004","volume":"45","author":"JY Reginster","year":"2009","unstructured":"Reginster JY, Bruyere O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone. 2009;45(6):1059\u201364. https:\/\/doi.org\/10.1016\/j.bone.2009.08.004.","journal-title":"Bone"},{"issue":"3","key":"2678_CR79","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00198-011-1847-z","volume":"23","author":"JY Reginster","year":"2012","unstructured":"Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int. 2012;23(3):1115\u201322. https:\/\/doi.org\/10.1007\/s00198-011-1847-z.","journal-title":"Osteoporos Int"},{"key":"2678_CR80","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","volume":"58","author":"C Roux","year":"2014","unstructured":"Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. Bone. 2014;58:48\u201354. https:\/\/doi.org\/10.1016\/j.bone.2013.10.006.","journal-title":"Bone"},{"issue":"9886","key":"2678_CR81","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","volume":"382","author":"JN Tsai","year":"2013","unstructured":"Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(13)60856-9.","journal-title":"Lancet"},{"issue":"10","key":"2678_CR82","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","volume":"7","author":"JN Tsai","year":"2019","unstructured":"Tsai JN, Lee H, David NL, Eastell R, Leder BZ. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019;7(10):767\u201375. https:\/\/doi.org\/10.1016\/S2213-8587(19)30255-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2678_CR83","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","volume":"101","author":"JR Tucci","year":"1996","unstructured":"Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC II. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med. 1996;101(5):488\u2013501. https:\/\/doi.org\/10.1016\/S0002-9343(96)00282-3.","journal-title":"Am J Med"},{"issue":"11","key":"2678_CR84","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","volume":"18","author":"Y Jiang","year":"2003","unstructured":"Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003;18(11):1932\u201341. https:\/\/doi.org\/10.1359\/jbmr.2003.18.11.1932.","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Orthopaedic Surgery and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-021-02678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13018-021-02678-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13018-021-02678-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T05:03:18Z","timestamp":1630040598000},"score":1,"resource":{"primary":{"URL":"https:\/\/josr-online.biomedcentral.com\/articles\/10.1186\/s13018-021-02678-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2678"],"URL":"https:\/\/doi.org\/10.1186\/s13018-021-02678-x","relation":{},"ISSN":["1749-799X"],"issn-type":[{"value":"1749-799X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors approved the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"533"}}